At the early stage of Omicron infection, IL-1β (Figure 7A) trended to decrease in both cancer patients and non-cancer-afflicted subjects; at the late stage, it remained at a low level without apparent fluctuation in cancer patients but trended to a marked increase in non-cancer-afflicted subjects. Here, IL1B is linked to cancer.